Search results for "fol"

showing 10 items of 7082 documents

Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years

2004

Background & aims: Increased morbidity and mortality from liver disease have been reported in chronic hepatitis B surface antigen (HBsAg) carriers, but data on survival are equivocal. To assess the impact of hepatitis B virus (HBV) infection on survival and liver-related complications, we re-evaluated, after a mean follow-up of 30 years, a cohort of 296 blood donors excluded from donation 30 years ago when HBsAg screening became mandatory. Methods: Clinical and ultrasound examination and biochemical and virologic tests were performed. The cause of death was recorded and survival was compared with a control population of 157 HBV-negative blood donors selected at baseline. Results: Thirty-two…

AdultMalevirus DNAmedicine.medical_specialtyHBsAgHepatitis B virusCirrhosisBlood Donorsmedicine.disease_causeGastroenterologyserum HBVCohort StudiesLiver diseaseHepatitis B ChronicInternal medicinemedicineHumansProspective StudiesSurvival analysisCause of deathAgedHepatitis B virusHepatitis B Surface AntigensHepatologybusiness.industryalcoholGastroenterologyHepatitis BMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseaseshepatitis B surface antigenItalygamma glutamyltransferaseHepatocellular carcinomaImmunologyCarrier StateFemalebusinessFollow-Up Studies
researchProduct

Optical coherence tomography of chorioretinal and choroidal folds

2007

. Purpose:  To report the optical coherence tomography (OCT) findings in cases of chorioretinal and choroidal folds. Methods:  Eight subjects with folds of the fundus of the eye were examined with fundus photography, fluorescein angiography, B-scan ultrasonography and Stratus OCT. Results:  Two types patterns were found on OCT. Five cases showed undulating retinal as well as retinal pigment epithelial lines of normal thickness; these were defined as chorioretinal folds. The posterior vitreous surface often adhered to the crests of the folds only. Three cases exhibited a wavy appearance of the retinal pigment epithelium and a flat retinal surface; these were classified as choroidal folds. Co…

AdultMalevisual acuitygenetic structuresFundus OculiDiagnosis Differentialchemistry.chemical_compoundRetinal DiseasesOptical coherence tomographyPhotographymedicineHumansFluorescein AngiographyPigment Epithelium of EyeAgedChoroidal foldsRetinal pigment epitheliummedicine.diagnostic_testSettore MED/30 - Malattie Apparato Visivobusiness.industryFundus photographyRetinalChoroid DiseasesAnatomyMiddle AgedFluorescein angiographyeye diseasesOphthalmologymedicine.anatomical_structureOCTchemistryFemalesense organsUltrasonographybusinessNormal thicknessTomography Optical CoherenceActa Ophthalmologica Scandinavica
researchProduct

Endoscopic Treatment of Mesencephalic Ependymal Cysts: Technical Case Report

1998

OBJECTIVE: To evaluate the results of different neuroendoscopic surgical procedures for the treatment of mesencephalic ependymal cysts. METHODS: The clinical records of five patients treated for symptomatic mesencephalic ependymal cysts were retrospectively studied. Two patients had been operated on using an endoscope-assisted microsurgical technique and three patients using a pure endoscopic procedure. RESULTS: Adequate fenestration of the cysts was achieved in all of the patients. Two of the patients were symptom-free, and the other three had improved significantly after a mean follow-up duration of 14 months. There was no surgical morbidity. CONCLUSION: Mesencephalic ependymal cysts can …

AdultMicrosurgerymedicine.medical_specialtymedicine.medical_treatmentCentral nervous system diseaseMesencephalonEpendymaHumansMedicineRetrospective StudiesBrain DiseasesCystsbusiness.industryEndoscopyMiddle AgedMicrosurgerymedicine.diseaseEndoscopic ProcedureSurgerySurgical morbidityTreatment OutcomeNeuroendoscopyFemaleSurgeryNeurology (clinical)FenestrationbusinessClinical recordEndoscopic treatmentFollow-Up StudiesNeurosurgery
researchProduct

Nasal airway in cleft-palate patients: acoustic rhinometric data

1997

The objective of this study was to investigate an instrumental assessment technique for acquiring reproducible, metric data on the nasal airway in cleft-palate associated nasal dysplasia. A consecutive sample of 23 unilateral, 17 bilateral CLP patients and 15 controls with subjective normal nasal patency from a cleft-palate rehabilitation centre were studied. A series of transnasal acoustic measurements (pressure wave: 55 dB for 2 ms) of nasal volume were performed before and after topical decongestion with 2 x 0.3 mg of xylometazoline. A standardized regimen of acoustic parameters of the nasal valve and the adjacent segment of the nasal cavity were calculated. The cleft side yielded a sign…

AdultNasal cavitymedicine.medical_specialtyAdolescentCleft Lipmedicine.medical_treatmentNoseRhinoplastyXylometazolineAcoustic rhinometryotorhinolaryngologic diseasesmedicineHumansLongitudinal StudiesChildNosemedicine.diagnostic_testbusiness.industryImidazolesNose Deformities AcquiredReproducibility of ResultsAcousticsHypertrophyrespiratory systemRhinoplastySurgeryCleft PalatePosterior segment of eyeballNasal DecongestantsNasal MucosaSoundmedicine.anatomical_structureOtorhinolaryngologySurgeryNasal CavityNasal ObstructionOral SurgeryRhinomanometryAirwaybusinessFollow-Up Studiesmedicine.drugJournal of Cranio-Maxillofacial Surgery
researchProduct

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

2011

Introduction: Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin's lymphoma in a real-life clinical setting. Methods: Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune…

AdultNephrologyrituximab; autoimmune diseasesmedicine.medical_specialtyHealth StatusImmunologyDrug ResistanceAutoimmune DiseasesDrug HypersensitivityAntibodies Monoclonal Murine-Derived03 medical and health sciences0302 clinical medicineRheumatologyimmune system diseaseshemic and lymphatic diseasesGermanyInternal medicinemedicineHumansImmunology and Allergyddc:610RegistriesRetrospective Studies030203 arthritis & rheumatologyAutoimmune diseasebusiness.industryRetrospective cohort studymedicine.diseaseRheumatology3. Good healthLymphomaPemphigusTreatment OutcomePatient SatisfactionAntirheumatic AgentsRheumatoid arthritisImmunologyRituximabRituximabbusinessImmunosuppressive Agents030217 neurology & neurosurgeryResearch ArticleFollow-Up Studiesmedicine.drugArthritis Research & Therapy
researchProduct

BRCA1 promoter methylation in peripheral blood is associated with the risk of triple‐negative breast cancer

2019

Methylation of the promoter of the BRCA1 gene in DNA derived from peripheral blood cells is a possible risk factor for breast cancer. It is not clear if this association is restricted to certain types of breast cancer or is a general phenomenon. We evaluated BRCA1 methylation status in peripheral blood cells from 942 breast cancer patients and from 500 controls. We also assessed methylation status in 262 paraffin‐embedded breast cancer tissues. Methylation status was assessed using methylation‐sensitive high‐resolution melting and was categorized as positive or negative. BRCA1 methylation in peripheral blood cells was strongly associated with the risk of triple‐negative breast cancer (TNBC)…

AdultOncologyCancer Researchmedicine.medical_specialtyConcordanceTriple Negative Breast Neoplasms03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBreast cancerInternal medicineBiomarkers TumormedicineHumansGenetic Predisposition to DiseaseBreastRisk factorPromoter Regions Geneticskin and connective tissue diseasesTriple-negative breast cancerAgedAged 80 and overBRCA1 Proteinbusiness.industryMethylationOdds ratioDNA MethylationMiddle Agedmedicine.diseaseOncologychemistryCase-Control Studies030220 oncology & carcinogenesisBiomarker (medicine)FemalebusinessDNAFollow-Up StudiesInternational Journal of Cancer
researchProduct

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positiv…

2015

Purpose Capecitabine is an active drug in metastatic breast cancer (BC). GEICAM/2003-10 is an adjuvant trial to investigate the integration of capecitabine into a regimen of epirubicin and docetaxel for node-positive early BC. Patients and Methods Patients with operable node-positive BC (T1-3/N1-3) were eligible. After surgery, 1,384 patients were randomly assigned to receive epirubicin plus cyclophosphamide (EC; 90 and 600 mg/m2, respectively, × four cycles), followed by docetaxel (100 mg/m2 × four cycles; EC-T) or epirubicin plus docetaxel (ET; 90 and 75 mg/m2, respectively, × four cycles), followed by capecitabine (1,250 mg/m2 twice a day on days 1 to 14, × four cycles; ET-X); all regime…

AdultOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentBreast NeoplasmsDocetaxelDisease-Free SurvivalDrug Administration ScheduleCapecitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsOdds RatiomedicineAdjuvant therapyHumansCyclophosphamideCapecitabineAgedEpirubicinNeoplasm StagingChemotherapybusiness.industryMiddle Agedmedicine.diseaseMetastatic breast cancerSurgeryRegimenTreatment OutcomeOncologyDocetaxelChemotherapy AdjuvantFluorouracilLymphatic MetastasisFemaleTaxoidsFluorouracilLymph NodesbusinessFollow-Up Studiesmedicine.drugEpirubicinJournal of Clinical Oncology
researchProduct

A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma

2006

We carried out a phase II nonrandomized study to examine the level of activity of oxaliplatin, pegylated liposomal doxorubicin, and cyclophosphamide in a patient population with relapsed ovarian cancer pretreated with platinum derivatives and paclitaxel. Patients received oxaliplatin (85 mg/m2), pegylated liposomal doxorubicin (30 mg/m2), and cyclophosphamide (750 mg/m2). A total of 49 patients (39 assessable for toxicity and response) were enrolled in this trial. Neutropenia grade 3 was observed in six patients (15%) and anemia grade 3 in one patient (0.2%). Fatigue grade 1–2 occurred in 26 patients (66%), nausea/vomiting grade 1 in 23 patients (58%), and alopecia grade 1–2 in 19 patients …

AdultOncologyTRIAL COMPARING CISPLATINmedicine.medical_specialtysecond-line therapy PLATINUM-BASED CHEMOTHERAPYOrganoplatinum CompoundsCyclophosphamidemedicine.medical_treatmentPhases of clinical researchAdenocarcinomaNeutropeniaPACLITAXELchemotherapyGastroenterologySINGLE-AGENTPolyethylene GlycolsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineEVALUATETOPOTECANCOMBINATIONCyclophosphamideAgedOvarian NeoplasmsChemotherapybusiness.industrySALVAGE CHEMOTHERAPYoxaliplatinObstetrics and GynecologyCombination chemotherapyMiddle Agedmedicine.diseaseSurvival AnalysisCANCEROxaliplatinRegimenliposomal doxorubicinovarian cancerOncologyDoxorubicinFemaleNeoplasm Recurrence LocalbusinessOvarian cancerFOLLOW-UPmedicine.drug
researchProduct

Association Between ABCB1 Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women With Breast Cancer

2020

Importance Persistent chemotherapy-induced alopecia (pCIA) has been recently described in patients with breast cancer and in its most severe form occurs in up to 10% of these patients. Genetic risk factors associated with pCIA have not been adequately explored. Objective To identify genetic variants associated with pCIA. Design, Setting, and Participants In this genetic association study, 215 women with breast cancer treated with docetaxel-based chemotherapy with a follow-up of 1.5 to 10 years after the end of the treatment were recruited retrospectively through 3 hospital oncology units across Spain between 2005 and 2018. Severe pCIA was defined as lack of scalp hair recovery (Common Termi…

AdultOncologymedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BBiopsyBreast NeoplasmsGenome-wide association studyDocetaxelDermatologyPolymorphism Single Nucleotide030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineBreast cancerRisk FactorsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansGenetic Predisposition to DiseasePromoter Regions GeneticAdverse effectRetrospective StudiesDose-Response Relationship Drugbusiness.industryAge FactorsCase-control studyAlopeciaCommon Terminology Criteria for Adverse EventsRetrospective cohort studyOdds ratioMiddle Agedmedicine.diseaseEnhancer Elements GeneticDocetaxelCase-Control Studies030220 oncology & carcinogenesisFemalebusinessHair FollicleFollow-Up StudiesGenome-Wide Association Studymedicine.drugJAMA Dermatology
researchProduct

BRCA1 gene-related hereditary susceptibility to breast and ovarian cancer in Latvia

2013

Abstract Purpose In this report, we summarise data on BRCA1 gene analysis in Latvia to characterise criteria of genetic testing for breast and ovarian cancer susceptibility. Material/methods Analysis by SSCP/HD, MALDI-TOF mass spectrometry or DNA sequencing was used for mutation detection. Mutations identified were confirmed by direct DNA sequencing. Results Out of 1068 breast and 231 ovarian cancer patients from different families: 58 carried the c.5266dupC and 43 carried the c.4035delA mutations. Every 4th patient in our study did not report cancer in the family. The breast cancer was diagnosed earlier in carriers of the c.5266dupC than in carriers of the c.4035delA ( p  = 0.003). The inc…

AdultOncologymedicine.medical_specialtyBreast NeoplasmsDiseasemedicine.disease_causePolymerase Chain ReactionBreast cancerInternal medicinemedicineHumansGenetic Predisposition to DiseaseFamily historyskin and connective tissue diseasesPolymorphism Single-Stranded ConformationalAgedGenetic testingAged 80 and overOvarian NeoplasmsMutationmedicine.diagnostic_testBRCA1 Proteinbusiness.industryCancerSingle-strand conformation polymorphismDNA NeoplasmGeneral MedicineMiddle AgedPrognosismedicine.diseaseLatviaMutationFemalebusinessOvarian cancerFollow-Up StudiesAdvances in Medical Sciences
researchProduct